These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35083576)

  • 1. Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal.
    Wang HX; Zhang L; Liang ZT; Nie JH; Wu JJ; Li QQ; Ding RX; Zhang Y; Chen GQ; Wang YC; Wang HG; Huang WJ
    Arch Virol; 2022 Feb; 167(2):459-470. PubMed ID: 35083576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination.
    Wang M; Zhang L; Li Q; Wang B; Liang Z; Sun Y; Nie J; Wu J; Su X; Qu X; Li Y; Wang Y; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):18-29. PubMed ID: 34818119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein.
    Liu J; Chen X; Liu Y; Lin J; Shen J; Zhang H; Yin J; Pu R; Ding Y; Cao G
    Infect Dis Poverty; 2021 Aug; 10(1):112. PubMed ID: 34419160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
    Wang Q; Ye SB; Zhou ZJ; Li JY; Lv JZ; Hu B; Yuan S; Qiu Y; Ge XY
    J Med Virol; 2023 Jan; 95(1):e28116. PubMed ID: 36056469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.
    Weissman D; Alameh MG; de Silva T; Collini P; Hornsby H; Brown R; LaBranche CC; Edwards RJ; Sutherland L; Santra S; Mansouri K; Gobeil S; McDanal C; Pardi N; Hengartner N; Lin PJC; Tam Y; Shaw PA; Lewis MG; Boesler C; Şahin U; Acharya P; Haynes BF; Korber B; Montefiori DC
    Cell Host Microbe; 2021 Jan; 29(1):23-31.e4. PubMed ID: 33306985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.
    Tang H; Gao L; Wu Z; Meng F; Zhao X; Shao Y; Shi X; Qiao S; An J; Du X; Qin FX
    Front Cell Infect Microbiol; 2021; 11():720357. PubMed ID: 34722330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies.
    Ding C; He J; Zhang X; Jiang C; Sun Y; Zhang Y; Chen Q; He H; Li W; Xie J; Liu Z; Gao Y
    Front Immunol; 2021; 12():693775. PubMed ID: 34484190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring Neutralizing Antibodies to SARS-CoV-2 Using Lentiviral Spike-Pseudoviruses.
    Neerukonda SN; Vassell R; Weiss CD; Wang W
    Methods Mol Biol; 2022; 2452():305-314. PubMed ID: 35554914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global Prevalence of Adaptive and Prolonged Infections' Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
    Lennerstrand J; Palanisamy N
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
    Wu K; Werner AP; Moliva JI; Koch M; Choi A; Stewart-Jones GBE; Bennett H; Boyoglu-Barnum S; Shi W; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
    bioRxiv; 2021 Jan; ():. PubMed ID: 33501442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization.
    Tang H; Gao L; Wu Z; Meng F; Zhao X; Shao Y; Hou G; Du X; Qin FX
    Front Immunol; 2022; 13():836232. PubMed ID: 35371108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift.
    Li T; Cui Z; Jia Y; Liang Z; Nie J; Zhang L; Wang M; Li Q; Wu J; Xu N; Liu S; Li X; An Y; Han P; Zhang M; Li Y; Qu X; Wang Q; Huang W; Wang Y
    J Med Virol; 2022 May; 94(5):2108-2125. PubMed ID: 35032057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells.
    Xiong HL; Wu YT; Cao JL; Yang R; Liu YX; Ma J; Qiao XY; Yao XY; Zhang BH; Zhang YL; Hou WH; Shi Y; Xu JJ; Zhang L; Wang SJ; Fu BR; Yang T; Ge SX; Zhang J; Yuan Q; Huang BY; Li ZY; Zhang TY; Xia NS
    Emerg Microbes Infect; 2020 Dec; 9(1):2105-2113. PubMed ID: 32893735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation.
    Huang SW; Miller SO; Yen CH; Wang SF
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity.
    Bhattacharya M; Chatterjee S; Sharma AR; Agoramoorthy G; Chakraborty C
    Appl Microbiol Biotechnol; 2021 Dec; 105(24):9035-9045. PubMed ID: 34755213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization.
    Wang Q; Ye SB; Zhou ZJ; Song AL; Zhu X; Peng JM; Liang RM; Yang CH; Yu XW; Huang X; Yu J; Qiu Y; Ge XY
    J Med Virol; 2023 Jan; 95(1):e28407. PubMed ID: 36519597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.